Is There a Risk That We're Not Seeing What We Want?

99 percent of companies pursuing in, i would say, like a a sud objective function. Is there a risk that we're going to not see what we want is the um going to produce useful things? Right? I think it's just more a question of the speed of the prog so if we can eventually come up with serge and points for clinical trials that are reasonable approximations to underlying increases in aging, or increases in mortality risk, might speed things up. And yet most, you know, yet, there still good programs.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app